Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Healthcare.com Corporation (Nasdaq: HCDC)was [HDIE] -- Ignore unavailable to you. Want to Upgrade?

To: TommyTurbo who wrote (8943)	1/9/1999 10:23:00 PM
From: Emec	Read Replies (2) \| Respond to of 15094

I posted this some time ago but newer thread folks may not have seen it since I don't think HDIE ever announced it. APACHE Medical Systems Cancels Proprietary Interface Engine Development - Partners with HIE to Incorporate HL7 Industry Standard Solution McLean, VA -- September 16, 1998 -- APACHE Medical Systems, Inc. [NASDAQ:AMSI], a leading provider of outcomes software and performance improvement services, today announced that it has cancelled proprietary interface engine development and entered into an agreement with Healthdyne Information Enterprises, Inc. (HIE) [NASDAQ: HDIE] to incorporate that Company's industry standard, HL7-compliant interface engine into the APACHE product line. "Developing interface engines is not a core competency of AMSI," said APACHE President and CEO Peter Gladkin. "Moving to an industry standard solution will enable APACHE to redeploy R&D resources into areas in which APACHE can get a better return on investment. At the same time, our customers will benefit from a more focused R&D effort resulting in more robust products." The Company said that the cancellation of in-house interface engine development is expected to have minimum impact on revenues and a positive impact on expenses going forward. APACHE Medical Systems, Inc. is the recognized leader in the development of risk-adjustment models, clinical decision support tools and quality improvement programs for the care of high-risk, high-cost patients. The Company's products and services enable health systems, hospitals and providers to apply an evidence-based approach to achieve clinical performance excellence, reduce cost and compete effectively under managed care. The Company's programs are today helping providers to better manage the clinical, financial and patient satisfaction outcomes of high-risk, high-cost patients in critical, acute, cardiovascular, HIV/AIDS and sub-acute care. In addition to the Company's clinical performance improvement services, APACHE/National Health Advisors offers strategic and management consulting services to strengthen the competitive position and operating performance of hospitals, health systems and other providers. APACHE's Health Outcomes Research division provides clinical trial design services and research support for product marketing and disease management programs for the pharmaceutical and medical device industries, as well as government research and database services. Statements in this press release which are not historical facts are forward- looking statements under provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements involve risks and uncertainties. The Company wishes to caution readers that the following important factors, among others, in some cases have affected, and in the future could affect, the Company's actual results and could cause its actual results in fiscal 1998 and beyond to differ materially from those expressed in any forward-looking statements made by, or on behalf of the Company. Important factors that could cause actual results to differ materially include but are not limited to the Company's having sufficient sales and timely collections to meet cash requirements and achieve profitability; ability to attract and retain key employees and to successfully replace its chief financial officer; success of its strategy to concentrate its product offerings on high-risk, high-cost patients; ability to timely develop new products and enhance existing products; ability to compete in the competitive and rapidly evolving healthcare information technology industry; ability to correctly estimate and manage its Year 2000 costs and liabilities; success of its marketing and consulting efforts and ability to effectively utilize its direct sales force; ability to protect proprietary information and to obtain necessary licenses on commercially reasonable terms; and ability to comply with and adopt products and services to potential regulatory changes.